- Home
- SCOR vs RNXT Comparison
SCOR vs RNXT Comparison
Compare SCOR & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCOR
- RNXT
- Stock Information
- Founded
- SCOR 1999
- RNXT 2012
- Country
- SCOR United States
- RNXT United States
- Employees
- SCOR N/A
- RNXT N/A
- Industry
- SCOR Business Services
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- SCOR Consumer Discretionary
- RNXT Health Care
- Exchange
- SCOR Nasdaq
- RNXT Nasdaq
- Market Cap
- SCOR 23.9M
- RNXT 44.6M
- IPO Year
- SCOR 2007
- RNXT 2021
- Fundamental
- Price
- SCOR $5.50
- RNXT $1.29
- Analyst Decision
- SCOR Buy
- RNXT Strong Buy
- Analyst Count
- SCOR 2
- RNXT 2
- Target Price
- SCOR $10.75
- RNXT $7.25
- AVG Volume (30 Days)
- SCOR 26.5K
- RNXT 150.4K
- Earning Date
- SCOR 08-05-2025
- RNXT 08-14-2025
- Dividend Yield
- SCOR N/A
- RNXT N/A
- EPS Growth
- SCOR N/A
- RNXT N/A
- EPS
- SCOR N/A
- RNXT N/A
- Revenue
- SCOR $354,961,000.00
- RNXT $240,000.00
- Revenue This Year
- SCOR $3.36
- RNXT $3,104.65
- Revenue Next Year
- SCOR $2.72
- RNXT $301.89
- P/E Ratio
- SCOR N/A
- RNXT N/A
- Revenue Growth
- SCOR N/A
- RNXT N/A
- 52 Week Low
- SCOR $4.39
- RNXT $0.75
- 52 Week High
- SCOR $15.31
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- SCOR 57.37
- RNXT 50.51
- Support Level
- SCOR $4.82
- RNXT $1.27
- Resistance Level
- SCOR $5.88
- RNXT $1.40
- Average True Range (ATR)
- SCOR 0.41
- RNXT 0.06
- MACD
- SCOR 0.02
- RNXT -0.01
- Stochastic Oscillator
- SCOR 61.26
- RNXT 40.59
About SCOR comScore Inc.
comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.